Abstract:Thalassemia syndromes are characterized by the inability to produce normal hemoglobin. Ineffective erythropoiesis and red cell transfusions are sources of excess iron that the human organism is unable to remove. Iron that is not saturated by transferrin is a toxic agent that, in transfusion-dependent patients, leads to death from iron-induced cardiomyopathy in the second decade of life. The availability of effective iron chelators, advances in the understanding of the mechanism of iron toxicity and overloading, and the availability of noninvasive methods to monitor iron loading and unloading in the liver, heart, and pancreas have all significantly increased the survival of patients with thalassemia. Prolonged exposure to iron toxicity is involved in the development of endocrinopathy, osteoporosis, cirrhosis, renal failure, and malignant transformation. Now that survival has been dramatically improved, the challenge of iron chelation therapy is to prevent complications. The time has come to consider that the primary goal of chelation therapy is to avoid 24-h exposure to toxic iron and maintain body iron levels within the normal range, avoiding possible chelation-related damage. It is very important to minimize irreversible organ damage to prevent malignant transformation before complications set in and make patients ineligible for current and future curative therapies. In this clinical case-based review, we highlight particular aspects of the management of iron overload in patients with beta-thalassemia syndromes, focusing on our own experience in treating such patients. We review the pathophysiology of iron overload and the different ways to assess, quantify, and monitor it. We also discuss chelation strategies that can be used with currently available chelators, balancing the need to keep non-transferrin-bound iron levels to a minimum (zero) 24 h a day, 7 days a week and the risk of over-chelation.

Heart failure secondary to severe anemia in beta-thalassemia major: a case report

Cardiac complications and iron overload in beta thalassemia major patients—a systematic review and meta-analysis

Cardiomyopathy and pericardial effusion in a 7 year-old boy with beta-thalassaemia major, severe primary hypothyroidism and hypoparathyroidism due to iron overload

Vitamin D levels and left ventricular function in beta-thalassemia major with iron overload

Arrhythmias and Sudden Cardiac Death in Beta-Thalassemia Major Patients: Noninvasive Diagnostic Tools and Early Markers

[Heavy metal! A case of severe iron overload and supraventricular arrhythmias in a thalassemia major patient]

Evaluation of some nonroutine cardiac biomarkers among adults and children with beta-thalassemia major

Cardiovascular magnetic resonance in β-thalassemia major: beyond T2

A Review of Iron Overload in Beta-Thalassemia Major, and a Discussion on Alternative Potent Iron Chelation Targets

Iron overload: the Achilles heel of β- thalassemia

The correlation of cardiac biomarkers and myocardial iron overload based on T2* MRI in major beta-thalassemia

Management of Iron Overload in Beta-Thalassemia Patients: Clinical Practice Update Based on Case Series

Cardiac complications in thalassemia throughout the lifespan: Victories and challenges

Beta-Thalassemia Major and Myocardial Iron Overload: A Longitudinal Study with Magnetic Resonance Imaging

High-output cardiac failure in the setting of iron deficiency anaemia: a case report

Thalassemia major between liver and heart: Where we are now

Anemia and iron overload as prognostic markers of outcomes in β-thalassemia

Prevalence of pulmonary hypertension in pediatric patients with beta-thalassemia major in Central India: a cross sectional study

Mortality and complications in Omani patients with beta-thalassemia major: a long-term follow-up study

Complications of β-thalassemia major in North America

Extensive systemic thrombo-embolism including intra-cardiac thrombosis mimicking an atrial myxoma in a patient with beta thalassaemia major - a case report